Glaucoma research opportunities

Glaucoma clinical trials recruiting in the United States

Explore currently listed glaucoma studies with reported U.S. locations and review public study and eligibility information. Compare age range, phase, sponsor, and public eligibility information before contacting an official study team.

44 recruiting studies 147 reported study locations

Find glaucoma studies near you

Enter a U.S. ZIP code to compare studies by distance from reported study sites.

Featured recruiting glaucoma studies

Age: 18 Years and olderPhase: PHASE3Reported sites: 29Sponsor: University of Pittsburgh

The goal of this study is to understand if SLT performed at low energy is as effective as SLT performed at standard energy, and also to see if repeating SLT at low energy once a year will prevent or delay the need for daily eye drop medications better than waiting for SLT to wear off before repeating it.

Age: 18 Years and olderPhase: PHASE3Reported sites: 22Sponsor: YS Life Science Co., Ltd.

This study is to establish non-inferiority of a preservative free formulation of Bimatoprost ophthalmic solution 0.01% (YSBP) of YS Life Science Co., Ltd. compared to LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of AbbVie INC in subjects with primary open angle glaucoma (POAG) or ocular hypertension.

Age: 45 Years and olderPhase: NAReported sites: 22Sponsor: Alcon Research

The purpose of this post-approval study is to evaluate the rate of Hydrus Microstent malposition and associated clinical sequelae occurring within 24 months post-operation. Qualified subjects will undergo uncomplicated cataract surgery with placement of a monofocal intraocular lens (IOL), followed by implantation of the Hydrus Microstent.

Age: 18 Years and olderPhase: PHASE3Reported sites: 9Sponsor: Amneal Pharmaceuticals, LLC

This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.

Age: 40 Years and olderPhase: NAReported sites: 7Sponsor: Massachusetts Eye and Ear Infirmary

The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset

Age: 18 Years – 88 YearsPhase: PHASE4Reported sites: 4Sponsor: University of Maryland, Baltimore

The purpose of this study is to establish autoregulation of retinal blood flow in arterioles and capillaries as a biomarker for early primary open angle glaucoma.

Age: 55 Years and olderPhase: NAReported sites: 4Sponsor: Nova Eye, Inc.

A prospective, multicenter, randomized, single-masked, post-market clinical trial comparing cataract surgery in conjunction with ab-interno canaloplasty utilizing the iTrack Advance canaloplasty device (Nova Eye, Inc.) to cataract surgery only in patients with mild to moderate, primary open angle glaucoma. Subjects will be followed for 24 months.

Age: 22 Years and olderPhase: PHASE3Reported sites: 1Sponsor: SpyGlass Pharma, Inc.

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Age: 18 Years and olderPhase: Not ApplicableReported sites: 1Sponsor: University of California, San Diego

The overarching goal of our research study is to evaluate changes in visual function and optic nerve topography (the structure of the back of the eye) in patients with glaucoma (increased susceptibility to pressure inside the eye that can cause loss of vision) or those with an increased risk of developing the disease. The purpose of this study is to determine the best methods for detecting the presence or progression (worsening over time) of glaucoma in patients with and without myopia and its effects on daily and…

Age: 18 Years and olderPhase: Not ApplicableReported sites: 1Sponsor: Brian Shafer

Background Glaucoma is a progressive optic neuropathy characterized by elevated intraocular pressure (IOP), leading to irreversible vision loss. Current treatment strategies often involve medications, which can be challenging for patients due to adherence issues and side effects. Direct Selective Laser Trabeculoplasty (DSLT) represents a potential surgical alternative for managing IOP in patients with naive, untreated glaucoma. This study aims to evaluate the efficacy of DSLT in achieving significant IOP…

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Glaukos Corporation

Adult subjects with elevated intraocular pressure will be randomized to receive iStent infinite trabecular bypass system plus a travoprost intraocular implant or receive a sham procedure plus a travoprost intraocular implant and be followed for 12 months.

Age: 21 Years and olderPhase: NAReported sites: 1Sponsor: Food and Drug Administration (FDA)

The objective of the study is to collect and assess adaptive optics (AO) retinal images from human subjects in support of projects to demonstrate, advance, and enhance clinical use of AO technology.

Age: 18 Years and olderPhase: Not ApplicableReported sites: 1Sponsor: Ophthalmology Associates, Fort Worth

This is a prospective, single-center, single-arm, observational study designed to evaluate the change in diurnal intraocular pressure (IOP) fluctuation following Direct Selective Laser Trabeculoplasty (DSLT) in patients with primary open-angle glaucoma (POAG) who are on 1-3 IOP lowering medications. The study will be conducted at one site and will involve three key visits: a screening visit, a baseline/treatment visit, and a 6-month follow-up visit. During the screening visit, patients will undergo a comprehensive…

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Indiana University

This study evaluates the effects of netarsudil (Rhopressa) on the trabecular meshwork in subjects with ocular hypertension or open-angle glaucoma. Participants will be randomized to receive either netarsudil or placebo (artificial tears). High-resolution imaging using adaptive optics gonioscopy, anterior segment optical coherence tomography (AS-OCT), and OCT gonioscopy will be performed at baseline and after approximately 14 days of treatment. The primary objective is to assess changes in trabecular meshwork…

Age: 18 Years and olderPhase: Not ApplicableReported sites: 1Sponsor: Marc Toeteberg-Harms

Subjects with a diagnosis of glaucoma will be handed out different quality of life related questionnaires and their score will be evaluated at baseline and 3-6 months after treatment or surgery was initiated/performed.

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Prairie Eye Center

A randomized, multi-site, parallel-group, prospective study of patients who are adults with a diagnosis of mild to moderate open-angle glaucoma (OAG), currently on an on-label use of combination topical medication of Cosopt and Latanoprost for a minimum of 1 month.

Age: 18 Years and olderPhase: PHASE1, PHASE2Reported sites: 1Sponsor: Regeneron Pharmaceuticals

This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension. REGN22530 is an experimental drug that is designed to bind with a protein in the eye that has been shown to cause a buildup of fluid inside the eye and cause increased Intraocular Pressure (IOP). REGN22530 attaches to this protein and stops it from working which may allow more fluid to drain out of the eye and decrease the pressure. The study is…

Age: 40 Years and olderPhase: Not ApplicableReported sites: 1Sponsor: Oregon Health and Science University

The specific aims of the clinical studies are to: * Develop a directional high-resolution OCT and OCT angiography prototype to improve imaging of structure and perfusion. * Validate wide-field OCT and OCT angiography parameters to improve early glaucoma detection. * Simulate visual field results by combining structural and angiography OCT data. * Assess abilities of above technologies and OCT-derived parameters on predicting glaucoma detection, conversion, and progression.

Age: 40 Years and olderPhase: NAReported sites: 1Sponsor: Twin Cities Eye Consultants

The GLASS Study is designed to help researchers learn whether repeating a non-invasive laser treatment called DSLT (Direct Selective Laser Trabeculoplasty) can better control eye pressure in patients with early-stage glaucoma or ocular hypertension. All participants will receive the laser treatment in both eyes. After three months, one eye will be randomly selected to receive a second treatment, while the other eye will serve as a comparison. The goal is to see whether two treatments work better than one at…

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Eye Centers of Southeast Texas

This is a randomized, double-masked, single-site, prospective, contralateral eye study designed to evaluate the outcomes of Direct Selective Laser Trabeculoplasty (DSLT) followed by the addition of combination netarsudil and latanoprost (Rocklatan) versus latanoprost monotherapy. The study will be conducted at one investigational site. The primary endpoint is the change in mean diurnal intraocular pressure (IOP) from baseline (post DSLT and post washout) at visit 3 between the two groups. Secondary endpoints…

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Mayo Clinic

The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).

Age: 18 Years and olderPhase: NAReported sites: 1Sponsor: Select Eye Care

The goal of this clinical trial is to to evaluate how well Direct Selective Laser Trabeculoplasty (DSLT) lowers eye pressure in eyes of adult, non-Caucasian participants with primary open angle glaucoma. The main question it aims to answer is: What is the washed out eye pressure (eye pressure when not on any glaucoma medications) of participants 6 months after the Direct Selective Laser Trabeculoplasty (DSLT) procedure compared to the washed out eye pressure of participants prior to the DSLT…

Age: 22 Years and olderPhase: PHASE3Reported sites: 1Sponsor: SpyGlass Pharma, Inc.

This trial is a randomized study to evaluate the Bimatoprost Implant System used in combination with the SpyGlass IOL to Timolol Ophthalmic Solution in participants with mild to moderate open-angle glaucoma or ocular hypertension undergoing cataract surgery.

Age: 18 Years and olderPhase: PHASE4Reported sites: 1Sponsor: Jonathon Myers

The Investigators will investigate the efficacy of combining the standalone iStent infinite and iDose that are minimally invasive surgical and drug depot options are a safe and effective alternative to filtering surgery for intraocuar pressure reduction in patients with medically uncontrolled open angle glaucoma.

Age: 18 Years and olderPhase: NAReported sites: 1Sponsor: University of Alabama at Birmingham

The goal of this clinical trial is to learn if implementation of an eye screening program at Federally Qualified Health Center (FQHC) clinics provides results that participants may have glaucoma, and/or other eye conditions (diabetic retinopathy, cataract, visual acuity impairment). The glaucoma screening will incorporate use of an artificial intelligence (AI)-assisted screening tool. This project is called AI-RONA. The main questions it aims to answer are: * How does this eye screening program compare to the…

Age: 40 Years and olderPhase: NAReported sites: 1Sponsor: Massachusetts Eye and Ear Infirmary

The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are: * How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare? * How do the safety profiles of these three microinvasive glaucoma surgeries compare? Participants will be randomized to…

Age: Not reportedPhase: Not ApplicableReported sites: 1Sponsor: Duke University

Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina. The investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the…

Age: 18 Years and olderPhase: NAReported sites: 1Sponsor: University of Maryland, Baltimore

The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: * Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow…

What eligibility can depend on

Each protocol is different. Study teams may consider diagnosis details, disease characteristics, prior treatments, age, general health, and the ability to attend required visits.

Before contacting a study

Review the official listing and consider having your diagnosis and treatment history available. Only the study team can confirm whether a trial may be appropriate.

Questions to ask

Ask about the study purpose, procedures, possible risks and benefits, visit schedule, travel, costs, and whether reimbursement is available.

Important: Varda Clinical is an independent discovery tool. It does not provide medical advice, recommend treatment, or determine eligibility. Verify study details with the official research team and discuss participation with a qualified healthcare professional.